From:  Extracellular vesicles as candidate mediators linking insulin resistance and metabolic dysfunction-associated steatotic liver disease

 Evolution of diagnostic frameworks for metabolic fatty liver disease and their relevance to extracellular vesicle research.

Designation (year)Originating frameworkDiagnostic logicConsequence for EV research
NAFLD (from 1980)Descriptive; subsequently codified in society guidanceHepatic steatosis with exclusion of significant alcohol intake and of competing aetiologiesExclusionary criteria yield cohorts heterogeneous with respect to metabolic burden, impairing comparability of vesicular endpoints
MAFLD (2020)International expert consensus, Asia-Pacific-ledSteatosis with overweight or obesity, type 2 diabetes, or two or more markers of metabolic dysregulation; coexisting liver disease permittedPositive metabolic criteria enrich for the insulin-resistant phenotype of principal relevance to vesicle-mediated communication
MASLD, MASH, MetALD (2023)Multisociety Delphi consensus (AASLD, EASL, ALEH)Steatosis with at least one of five cardiometabolic criteria; MetALD delineates the group with higher alcohol intakeDelineation of MetALD separates a group in which alcohol exposure independently influences hepatocyte vesicular release

AASLD: American Association for the Study of Liver Diseases; ALEH: Latin American Association for the Study of the Liver; EASL: European Association for the Study of the Liver; MetALD: metabolic and alcohol-related liver disease.